Prostate Cancer | Specialty

Dr. Taplin on ARMOR 3-SV Trial for Patients with mCRPC

July 11th 2016

Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Loppenberg on Benefits of Local Treatment for Metastatic Prostate Cancer

July 11th 2016

Dr. Saad on Patients With mCRPC Eligible for 6-Doses of Radium-223

July 8th 2016

Fred Saad, MD, professor and chairman of Urology, director of GU Oncology, the University of Montreal Hospital Centers, discusses results of an analysis that examined which patients with metastatic castration-resistant prostate cancer are able to receive the recommended 6-doses of radium-223 dichloride (Xofigo).

Shore Shares Insight on Challenges of Bone Metastases in mCRPC

July 6th 2016

Bone metastases in castration-resistant prostate cancer create a significant problem, and a rising incidence of men are developing advanced disease.

GU Cancer Treatments Advance, But Their Application Remains Unclear

July 5th 2016

Even as our understanding of the biology of prostate and bladder cancers improves and treatment protocols are refined, there remain many clinical scenarios in which no clear-cut answers are available.

Dr. Marc Bjurlin on Predictive Models for Prostate Cancer Risk

June 29th 2016

Dr. Stacy Loeb on Screening Considerations in Prostate Cancer

June 28th 2016

Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer

June 23rd 2016

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer

HHS Rejects Bid to Broaden Access to Enzalutamide

June 23rd 2016

The Department of Health and Human Services has turned down a request to override the patent for prostate cancer drug enzalutamide (Xtandi) so that it can be sold to a broader base of patients at a reduced price.

Factors Predict Patients Fit for Full 6 Cycles of Radium-223 in mCRPC

June 22nd 2016

In metastatic castration-resistant prostate cancer, pain and hemoglobin levels, PSA levels, and ECOG performance status may predict which patients will be able to receive the recommended 6-dose regimen of radium-223 dichloride (Xofigo).

Dr. Sartor on Mechanism of Action and Safety of Radium-223 in mCRPC

June 21st 2016

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Safety, Survival Advantages of Radium-223 Continue to Offer Benefit in mCRPC

June 21st 2016

Richard G. Stock, MD, discusses the ideal patient for radium-223 dichloride (Xofigo), its proper sequencing with metastatic castration-resistant prostate cancer, and the future outlook for the therapy.

ADT Increases Risk for Depression in Elderly Men With Localized Prostate Cancer

June 21st 2016

Although androgen deprivation therapy has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether it causes clinically significant depression.

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

June 20th 2016

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Second-Generation AR-Targeting Agent Explored in High-Risk Prostate Cancer

June 15th 2016

Researchers are hoping the results of a late-stage efficacy and safety study of apalutamide in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival.

Abiraterone Regimen Demonstrates Safety, Activity in CRPC

June 14th 2016

A combination regimen involving abiraterone acetate (Zytiga) and low-dose prednisone demonstrated a median time to radiographic progression of 41.4 months, as well as a median time to prostate-specific antigen progression of 28.7 months, in men with nonmetastatic castration-resistant prostate cancer.

A Look Ahead in Genitourinary Cancers

June 1st 2016

The Role of Biomarkers in Bladder Cancer

June 1st 2016

Measuring Response in Non-Muscle Invasive Bladder Cancer

June 1st 2016

Approaches in High-Risk Non-Muscle Invasive Bladder Cancer

June 1st 2016